BCS1L and breast cancer: Experimental validation in breast cancer cell models demonstrated that both ligands reduced cell viability; ligand 1 showed enhanced effects in C2-overexpressing cells, consistent with predicted accessibility, whereas ligand 2 partially counteracted the C2 domain-induced viability phenotype, likely via interference with PTD-mediated interactions.